SCHEMBL24717417

SCHEMBL24717417

COC(=O)c1ccc([C@@H]2CCN(C(=O)OC(C)(C)C)C[C@H]2O)cc1C(=O)OC

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE4B Q07343 8/20 0.45
▸ JAK2 O60674 1/20 0.43
▸ JAK3 P52333 1/20 0.43
▸ PTK2 Q05397 1/20 0.43
▸ EED O75530 1/20 0.43
▸ RBBP4 Q09028 1/20 0.43
▸ SUZ12 Q15022 1/20 0.43
▸ EZH2 Q15910 1/20 0.43
▸ AEBP2 Q6ZN18 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.42
▸ TACR1 P25103 1/20 0.42
▸ PTPN2 P17706 1/20 0.41
▸ PTPN1 P18031 1/20 0.41
▸ PTPN6 P29350 1/20 0.41
▸ NR1H2 P55055 2/20 0.40
▸ NR1H3 Q13133 1/20 0.40
▸ NAMPT P43490 1/20 0.40
▸ ENPP2 Q13822 1/20 0.39
▸ STS P08842 1/20 0.39
▸ GPR119 Q8TDV5 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30798370 1.00 PDE4B (0.45) PDE4BJAK2JAK3PTK2EED
SCHEMBL30798625 1.00 PDE4B (0.45) PDE4BJAK2JAK3PTK2EED
SCHEMBL29152533 1.00 PDE4B (0.45) PDE4BJAK2JAK3PTK2EED
SCHEMBL24717421 1.00 PDE4B (0.45) PDE4BJAK2JAK3PTK2EED
SCHEMBL30606458 0.91 PDE4B (0.53) PDE4BJAK2JAK3PTK2EED
SCHEMBL29152603 0.91 JAK2 (0.43) PDE4BJAK2JAK3PTK2EED
SCHEMBL30798402 0.91 JAK2 (0.43) PDE4BJAK2JAK3PTK2EED
SCHEMBL16991907 0.91 PDE4B (0.53) PDE4BJAK2JAK3PTK2EED
SCHEMBL24717418 0.88 PDE4B (0.45) PDE4BEEDRBBP4SUZ12EZH2
SCHEMBL24717414 0.88 PDE4B (0.45) PDE4BEEDRBBP4SUZ12EZH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220395576-A1 MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2022-12-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220395576-A1 MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE BCL6, BCL6B, BCL3 PDE4B 4172/4885JAK2 916/4885JAK3 1959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback